News for Gossamer Bio, Inc. (GOSS)

We recently published a list of the 11 Best Penny Stocks to Invest in Under $1. In this article, we are going to take a look at where Gossamer Bio Inc.

We recently published a list of 10 Stocks Under $10 that Will Triple. In this article, we are going to take a look at where Gossamer Bio, Inc. (NASDAQ:GOSS) stands against other stocks under $10 that will triple. As we delve into the discussion on stocks that will triple, we must shed light on the […]

The biotechnology sector is gaining new momentum with better market conditions, cutting-edge innovations, and growing investor attention.

We recently published a list of 10 Penny Stocks With Huge Upside Potential According To Analysts. In this article, we are going to take a look at where Gossamer Bio, Inc.

**media[568943]**

Revenue: Achieved $9.38 million for the quarter, surpassing the estimated $6.83 million.Earnings Per Share (EPS): Reported a net loss of $0.15 per share, bette

[url="]Gossamer Bio, Inc.[/url] (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutini

Gossamer Bio (GOSS) delivered earnings and revenue surprises of 11.76% and 19.63%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

[url="]Gossamer Bio, Inc.[/url] (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutini

**media[544182]**

MIAMI, Feb. 19, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 79th Emerging Growth Co

MIAMI, Feb. 18, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 79th Emerging Growth Co

Gossamer Bio's Seralutinib shows promise for PAH and PH-ILD treatment. The main event comes with its topline results in Q4 2025. Read more on GOSS stock here.

[url="]Gossamer Bio, Inc.[/url] (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for

[url="]Gossamer Bio, Inc.[/url] (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for

We recently compiled a list of the 12 Best Penny Stocks to Invest in According to the Media. In this article, we are going to take a look at where Gossamer Bio, Inc.

Gossamer Bio (GOSS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Seralutinib becomes XOMA Royalty's seventh Phase 3 royalty asset, further building the late-stage pipeline beyond its six current commercial royalty assets

Gossamer Bio (GOSS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).